Ultimovacs ASA (OSL: ULTI)

Market Cap	75.69M
Revenue (ttm)	n/a
Net Income (ttm)	-149.28M
Shares Out	34.41M
EPS (ttm)	-4.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	600,804
Open	2.050
Previous Close	2.070
Day's Range	2.050 - 2.405
52-Week Range	1.570 - 165.000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2024

About Ultimovacs ASA

Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 27
• Stock Exchange: Oslo Børs
• Ticker Symbol: ULTI